Pierre Fabre
New ways to care  

In line with Pierre Fabre Laboratories' vision "Every time we care for a single person, we make the whole world better" the MSL (Medical Science Liaison) role is crucial in enhancing patient care. As a scientific bridge between the medical community and the Pierre Fabre Laboratories, the MSL combines pharmaceutical innovation with medical expertise to develop collaboration with healthcare professionals and optimize daily healthcare practices. The MSL's objectives can be achieved through various missions, including: Medical Education: promoting best practices for up-to-date patient management. Insight Collection: gaining a comprehensive understanding of patient treatment practices, organization, and patient journey. Data Needs Identification and participation to their generation to promote best practices for patient treatment. Support Clinical Development and Real-World Evidence Projects. Understanding patient needs. Click to discover in this infographic the multifaceted life of our MSLs, their missions, skills, and roles at Pierre Fabre Laboratories.   Dive into the MSL experience through a series of 10 monthly interviews. The series will share their professional journeys, highlighting the realities and successes they encounter, and provide a glimpse into their commitment to advancing medical care.   #1  Emeline Mathieu: A Passionate Medical Science Liaison (MSL) Advancing Healthcare in Australia.  #2  Pawel Pedrasik: A Passionate Medical Science Liaison (MSL) Advancing Healthcare in Poland #3 Zohra Butt: A Medical Science Liaison (MSL) Dedicated to Changing Patient Lives in the United Kingdom.  #4 Miaomiao Zhang: A Medical Science Liaison (MSL) Transforming the Therapeutic Landscape in China.

    The script of video. •    Could you please introduce yourself? Hello, I am Anne-Sophie Paradis. I’m 37 years old. I’m a pharmacist from France, and I have worked as an MSL for Pierre Fabre for nearly 2 years.  •    What is your professional background before being an MSL?  I previously worked in the pharmaceutical industry, mainly in clinical trials. I started as clinical research associate and evolved later to a clinical project manager position.  •    How would you define the MSL role? The MSL is the scientific local key contact for the healthcare professionals of certain diseases, and the link with the pharmaceutical company. His role is to identify medical needs and support the building of scientific projects to help improve patient care.  •    What do you like about being an MSL? What I like the most about being an MSL is to build scientific collaboration with healthcare professionals, have various scientific and medical discussions, and projects depending on healthcare professional needs.  •    What is the most difficult thing for you about being an MSL? Administrative work, which is also an important part of the job.  •    What is the essential quality of an MSL for you? In my opinion, adaptability is the essential quality of an MSL.  •    What motivates you to get up in the morning as an MSL? I am motivated by scientific and medical discussions with Key Opinion Leaders, strategic involvement, by learning about medical news and by collaborating on medical projects to improve patient care.  •    What is your most beautiful emotion experienced as an MSL? Job fulfillment. Following a multidisciplinary meeting I organized, when health care professionals shared their practices, they told me they were satisfied about the content of the meeting. And what’s more, that they were willing to participate to the same kind of meeting next year.  •    Any words or advice for someone wanting to become an MSL? I would advise to have good relationship, rigor and adaptability skills, to be open-minded and to work on the field in order to have a good understanding of hospital structure.     Know more about MSL

  The script of video. •   Could you please introduce yourself? My name is Javier. I’m 48 years old, and I’ve been working at Pierre Fabre Oncology in Spain for 14 years.  •    What is your professional background before being an MSL?  The first 5 years at Pierre Fabre, I worked as a Key Account Manager, in charge of sales and market access responsibilities, until I jumped to MSL 9 years ago. Before Pierre Fabre, I worked in 2 other pharmaceutical companies, also as a Key Account Manager.  •    How would you define the MSL role? The MSL is the scientific reference for the Key Opinion Leaders in everything related to our drugs, pharmacology and mechanism of action, treatment management, new data provided by research, clinical development, etc… In addition, I would like to highlight the cross-functional work with other departments of Pierre Fabre Oncology.  •    What do you like about being an MSL? I like so much being able to exchange relevant information with healthcare professionals and discuss with them. Internally, I also like playing an important role at a transversal level. For example, by participating in an international mentoring program.  •    What is the most difficult thing for you about being an MSL? Sometimes it’s complicated to balance office time and time on field. Furthermore, when you are responsible for several pathologies, maintaining a high level of scientific knowledge requires a great effort.  •    What is the essential quality of an MSL for you? High qualification, objectivity, resilience, perseverance, versatility and teamwork.  •    What motivates you to get up in the morning as an MSL? The pride of working for a company which help patients in their fight against cancer, and secondly, in line with the Pierre Fabre’s values: “Every time we care for a single person, we make the whole world better”.  •    What is your most beautiful emotion experienced as an MSL? I remember experiencing firsthand the presentation of positive data on the treatment of CRC, at ESMO Barcelona 2019, which we were published that same day.  •    Any words or advice for someone wanting to become an MSL? It's a very demanding but dynamic job, which for sure will allow you to fulfill yourself on a daily basis and grow professionally, so…. go for it!     Know more about MSL

  Join us for a deep dive experience into our incredible colon ! Colorectal Cancer Facts and Figures 1.9 million Is approximately the number of cases diagnosed annually, of which 520,000 are diagnosed in Europe.1 More than 3 million Estimated number of new cases globally per year by 2040.2 Increase in adults under 50 years old Number of cases under 50’s has been rising by about 1.5% each year since the 90s.3 Colorectal cancer (CRC) is the third most common cancer worldwide with more than 1.9 million new cases in 2022.1 It is also the 2nd most deadly cancer in the world with over 900 000 deaths in 2022.1 Pierre Fabre Laboratories’ commitment to colorectal cancer As in previous years, Pierre Fabre Laboratories are committed once again to raising public awareness of CRC prevention and screening, and to supporting the actions carried out by patient associations through the Blue March campaign "The wonderful colon". The objective of the “Wonderful Colon” campaign  Our objective is to invite the general public to take part in an immersive experience to discover this wonderful and not well-known organ and how to take care of it.  Through a deliberately positive and playful approach, the user will be able to learn more about how this organ works, why and how to take care of it, before tackling the subject of colorectal cancer, from its detection to its treatment. It is important to raise awareness around reducing the risk and early diagnosis of CRC as early detection results in better outcomes than if diagnosed after the disease has metastasized.2  There are a range of everyday actions and activities that can help reduce the risk of colorectal cancer.4 Whatever their habits, lifestyle choices or individuality, everyone can do something to participate in CRC prevention and screening. To learn more and take part in the diving experience, visit www.thewonderfulcolon.com/en Our goal is still the same, Every time we care for a single person, we make the whole world better. References :1.    Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834.2.    Gunter MJ, et al. Ann Oncol. 2019;doi: 10.1093/annonc/mdz044.3.    Gallois A, et al. Cancer Treat Rev. 2024:130:102821. doi: 10.1016/j.ctrv.2024.102821.4.    Kerr J, et al. Lancet Oncol. 2017; 18(8):e457–71. doi: 10.1016/S1470-2045(17)30411-4. HQ-01-25-2500054